GlassScriptPhysician profile
Steven Waxenbaum
NPI 1952373466
$10,850.19
in general payments reported to CMS, 2019-2025
22 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $104 · 2021: $7,589 · 2022: $457 · 2023: $384 · 2024: $1,792 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,027 · Consulting Fee: $650 · Travel and Lodging: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,027.17 |
| Consulting Fee | $650.00 |
| Travel and Lodging | $642.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,234.02 | 2021 | |
| Stryker Corporation | $849.90 | 2024 | 1788 |
| Medtronic, INC. | $843.19 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.10 | 2019-2025 | Xifaxan, Plenvu |
| Abbvie INC. | $262.96 | 2021-2024 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $159.96 | 2021-2025 | Stelara, Tremfya, Remicade |
| Olympus America INC. | $136.77 | 2019 | |
| Boston Scientific Corporation | $130.96 | 2023 | Watchman |
| Takeda Pharmaceuticals U.S.A., INC. | $129.29 | 2021-2024 | Entyvio |
| Merck Sharp & Dohme LLC | $129.08 | 2019-2024 | Dificid, Zinplava |
| Sanara Medtech INC. | $124.80 | 2024 | Celleraterx |
| Ethicon US, LLC | $105.20 | 2019-2021 | |
| Celgene Corporation | $101.78 | 2021-2023 | Zeposia |
| Redhill Biopharma INC. | $42.94 | 2020-2023 | Movantik, Aemcolo, Talicia |
| Braintree Laboratories, INC. | $41.43 | 2021-2023 | Sutab, Suflave |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acell, INC. | $23.01 | 2019 | |
| Thd America, INC. | $20.88 | 2019-2020 | |
| Convatec INC. | $20.72 | 2019 | |
| Axonics, INC. | $17.68 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $15.87 | 2022 | |
| Baudax Bio INC. | $15.00 | 2020 | |
| Ethicon INC. | $14.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Waxenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.